Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Jan 27;17(1):e0262990. doi: 10.1371/journal.pone.0262990

Increased prevalence of transfusion-transmitted diseases among people with tattoos: A systematic review and meta-analysis

Sung Ha Lim 1,#, Solam Lee 1,2,#, Young Bin Lee 1, Chung Hyeok Lee 1, Jong Won Lee 1, Sang-Hoon Lee 1, Ju Yeong Lee 1, Joung Soo Kim 3, Mi Youn Park 4, Sang Baek Koh 2, Eung Ho Choi 1,*
Editor: Maria R Khan5
PMCID: PMC8794209  PMID: 35085358

Abstract

Whether having a tattoo increases the risk of transfusion-transmitted diseases (TTDs) is controversial. Although a few studies have suggested a strong association between having tattoos and TTDs, other studies have not shown the significance of the association. In addition, previous studies mainly focused only on hepatitis C viral infections. The objective of our study was to identify the prevalence and risk of TTDs in people with tattoos as compared with the non-tattooed population. A systematic review of the studies published before January 22, 2021, was performed using the Pubmed, Embase, and Web of Science databases. Observational studies on hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), and syphilis infections in people with and without tattoos were included. Studies that reported disease status without serological confirmation were excluded. A total of 121 studies were quantitatively analyzed. HCV (odds ratio [OR], 2.37; 95% confidence interval [CI], 2.04–2.76), HBV (OR, 1.55; 95% CI, 1.31–1.83), and HIV infections (OR, 3.55; 95% CI, 2.34–5.39) were more prevalent in the tattooed population. In subgroup analyses, the prevalence of HCV infection was significantly elevated in the general population, hospital patient, blood donor, intravenous (IV) drug user, and prisoner groups. IV drug users and prisoners showed high prevalence rates of HBV infection. The prevalence of HIV infection was significantly increased in the general population and prisoner groups. Having a tattoo is associated with an increased prevalence of TTDs. Our approach clarifies in-depth and supports a guideline for TTD screening in the tattooed population.

Introduction

Tattoos are becoming rapidly popular among young people, as they have become recognized as a means of self-expression [1, 2]. According to a worldwide survey conducted in 2019 [3], the prevalence of tattoos was reported to range from 12.2% to 31.5% depending on the region. A population-based study found that more than one-third of young adults in the United States have tattoos [4]. Tattooing is an invasive procedure that involves the injection of pigmentary particles into the dermal layer of the skin through repeated skin punctures. Therefore, it poses a potential risk of infection by diverse microorganisms if the ink or instrument used for tattooing is reused without a proper disinfection procedure.

Transfusion-transmitted diseases (TTDs) are blood-borne infectious diseases that include hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), and syphilis infections [5, 6]. In 2016, 1.90 million patients with HCV infection in the United States were identified, but only 49.8% of them knew about their disease status [7]. Moreover, 1.10 million patients with HIV infection were also reported, but one-seventh of them were not aware of their infection [8]. The most important risk factor for the transmission of TTDs has been known as sharing needles and equipment for drug use.

However, whether having tattoos increases the risk of transmission of TTDs is still controversial. A few studies have suggested a strong association between having tattoos and TTDs [913]; however, other studies have not shown the significance of the association [1416]. Some systematic reviews and meta-analyses [1720] have reported that tattooing in certain groups could increase the risk of HCV transmission. However, previous studies were mainly limited to HCV infection, and studies performing comprehensive evidence syntheses, including other TTDs, using a uniform methodology are currently lacking. Therefore, the purpose of this systematic review and meta-analysis was to investigate the prevalence and risk of HCV, HBV, HIV, and syphilis infections in people with tattoos as compared with the non-tattooed population.

Materials and methods

Search strategy

We performed a comprehensive literature search in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines. The Pubmed, Embase, and Web of Science databases were searched. One of the main reviewers (S.L.) performed the literature search, using the following search keywords: “tattoo*,” “HIV,” “AIDS,” “immunodef*,” “hepatitis,” “HCV,” “HBV,” “HBsAg,” “syphilis,” “VDRL,” “TPHA,” “treponema*,” “transfu*,” “blood*,” and “infect*.” The detailed search strategies for the databases are summarized in S1 File. The literature search included the studies published until January 22, 2021. Articles written in English and Korean were included because of the authors’ proficiencies in these languages.

Study selection

Four main reviewers (S.L., S.H.L., Y.B.L., and C.H.L.) evaluated the titles and abstracts of the retrieved studies. All individual studies were independently reviewed by at least two reviewers. Any disagreements between the reviewers regarding the suitability of the studies were discussed with two other reviewers (J.W.L. and S.H.L.) and resolved by consensus. All the observational studies on HCV, HBV, HIV, and syphilis infections that investigated both individuals with and without tattoos were included. Meanwhile, the following studies were excluded: 1) non-research articles, 2) studies that reported disease status without serological confirmation (e.g., self-response questionnaire), 3) studies that only investigated either subjects with or without tattoos (non-comparability), and 4) studies with insufficient sample sizes (n < 20).

Data extraction and quality assessment

Data regarding publication details, study setting, population demographics, and serological findings were extracted from each study. The number of events (positive in serology) and total observations for HCV, HBV, HIV, and syphilis infections in both the tattooed and non-tattooed groups were extracted from case-control, cross-sectional, and case-series studies. For cohort and any other studies that performed a time-to-outcome analysis, the hazard ratio (HR) for each finding was directly extracted. The adapted Newcastle-Ottawa scale for assessing the quality of observational studies was used for the assessment of the analyzed studies [21]. Finally, the articles with adequate quality (score ≥ 3) were included in the quantitative meta-analysis.

Data synthesis and outcomes

For case-control, cross-sectional, and case-series studies, we calculated the odds ratio (OR) as a summary statistical variable for comparing the prevalence of TTDs in the tattooed and non-tattooed populations. The HRs obtained from each study were to be meta-analyzed with time-to-outcome analysis. A random-effects model was used in the meta-analysis because a significant heterogeneity between the included studies was expected. The I2 statistics was used to estimate and quantify the heterogeneity between the studies. Subgroup analyses (general population, hospital patients, blood donors, intravenous (IV) drug users, and prisoners) for the study populations (≥3 studies) were performed to address the heterogeneity. General population were those who were included population-based (community) studies. In contrast to other subgroups, which are within characteristic environments that favor an increased prevalence of TTDs in the tattooed population, we thought it is worth estimating the prevalence in a sample which can be approximated to the general population. Egger’s linear regression test was performed to evaluate publication bias. The trim-and-fill method was used to adjust the summary statistics when a significant publication bias was detected. The analysis was performed using R version 3.5.0 (R Foundation for Statistical Computing). A p value of <0.05 was considered statistically significant.

Code and data availability

The final datasheet for extraction, program code used for the quantitative synthesis, and forest plots for individual analyses can be accessed at our public repository at https://doi.org/10.17632/cgpp4fzxhd.1.

Results

Study selection and characteristics

The PRISMA flow diagram is presented in Fig 1. Among the 2,030 publications screened, 798 full-text articles were assessed for eligibility. A total of 121 studies were quantitatively analyzed (Tables 1 and S1 and S2). However, none was a cohort study that included a time-to-outcome analysis. The adapted Newcastle-Ottawa scale for assessing the quality of the included cross-sectional studies is presented in S3 Table. The summary statistics for the HCV, HBV, HIV, and syphilis infections in the tattooed group as compared with the non-tattooed group are shown in Fig 2.

Fig 1. PRISMA flowchart for study selection.

Fig 1

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of literature search and study selection.

Table 1. Summary of the included studies.

Variables N % Variables N %
Countries 121 100 Study populations 116 100
Iran 23 19.0 General population 36 31.0
Brazil 13 10.7 Hospital patients 24 20.7
U.S.A. 12 9.9 Blood donors 6 5.2
India 9 7.4 Intravenous drug users 25 21.6
Australia 6 5.0 Prisoners 25 21.6
Mexico 5 4.1 Disease
Taiwan 5 4.1 HCV 86
Thailand 5 4.1 Anti-HCV 81 94.2
Nigeria 4 3.3 HCV-RNA 5 5.8
Pakistan 3 2.5 HBV 48
Bosnia 2 1.7 HBsAg 38 79.2
Canada 2 1.7 Anti-HBc 6 12.5
Ethiopia 2 1.7 HBV-DNA 3 6.3
France 2 1.7 HBs Ab 1 2.1
Italy 2 1.7 HIV 20
Spain 2 1.7 Anti-HIV 20 100
Others 24 19.8 Syphilis 3
RPR, VDRL test 3 100

Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus; RPR, rapid plasma regain; VDRL, venereal disease research laboratory.

Fig 2. Forest plots summarizing the meta-analysis.

Fig 2

Forest plots of the meta-analysis. (A) HCV, (B) HBV, (C) HIV, and (D) Syphilis. Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus.

HCV infection

A total of 86 studies that reported HCV serostatus were meta-analyzed (Fig 2A). HCV infection was significantly more prevalent in the tattooed group than in the non-tattooed group (meta-analyzed OR, 2.89; 95% confidence interval [CI], 2.48–3.37). However, a possible publication bias among the studies that reported HCV serostatus was suggested by the funnel plot (Fig 3A) and Egger’s test (p = 0.01). Nevertheless, HCV infection was still more prevalent in the tattooed group even after adjustment for publication bias using the trim-and-fill method (adjusted OR, 2.37; 95% CI, 2.04–2.76). Likewise, all the subgroup analyses revealed a statistically significant increase in the prevalence of HCV infection in the tattooed group as compared with the non-tattooed group (Table 2).

Fig 3. Funnel plots for the assessment of publication bias.

Fig 3

Funnel plots of the meta-analyses. (A) HCV, (B) HBV, and (C) HIV. Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus.

Table 2. Meta-analyzed estimates of the prevalence rates of transfusion-transmitted diseases among subjects with tattoos.

Disease Subgroupa No. of studies No. of tattoo users No. of controls OR (95% CI) I 2 Egger’s test
HCV (All) 86 30665 171103 2.89 (2.48–3.37) 85% 0.01
b2.37 (2.04–2.76)
General population 18 5812 31492 2.94 (2.32–3.73) 70% 0.43
Hospital patients 16 4919 46114 4.27 (3.21–5.68) 53% 0.71
Blood donors 5 812 67477 3.27 (1.48–7.21) 77% 0.85
Intravenous drug users 22 3733 3501 2.37 (1.54–3.67) 92% 0.08
Prisoners 19 12890 13275 2.99 (2.50–3.56) 66% 0.12
HBV (All) 48 25886 91495 1.55 (1.31–1.83) 84% 0.19
General population 16 5185 43828 2.04 (1.42–2.93) 85% 0.04
b1.41 (0.98–2.03)
Hospital patients 12 2475 27141 1.97 (1.15–3.37) 91% 0.04
b0.91 (0.54–1.53)
Intravenous drug users 6 1276 1166 1.40 (1.13–1.74) 0% 0.02
b1.46 (1.16–1.83)
Prisoners 9 14336 13923 1.35 (1.07–1.70) 74% 0.15
HIV (All) 20 6917 17873 3.55 (2.34–5.39) 85% 0.10
General population 5 1010 6976 2.73 (1.35–5.54) 64% 0.71
Hospital patients 3 874 2548 5.71 (0.87–37.47) 86% 0.20
Intravenous drug users 3 490 581 4.33 (0.21–88.3) 95% 0.67
Prisoners 5 3712 4069 4.29 (3.32–5.54) 0% 0.21
Syphilis (All) 3 692 2203 1.55 (0.76–3.17) 0% -

Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus

aSubgroup analyses were performed when three or more studies were available for each subgroup.

bAdjusted OR with the trim-and-fill method for possible publication bias.

HBV infection

In total, 48 studies that reported HBV serostatus were meta-analyzed (Fig 2B). HBV infection was significantly more prevalent in the tattooed group than in the non-tattooed group (meta-analyzed OR, 1.55; 95% CI, 1.31–1.83).

Similarly, all the subgroup analyses revealed an increased prevalence of HBV infection in the tattooed group as compared with the non-tattooed group (Table 2). However, a possible publication bias was suggested for the studies that reported HBV serostatus among general population subgroup (Egger’s test, p = 0.04), hospital patients (Egger’s test, p = 0.04), and IV drug users (Egger’s test, p = 0.02). Nevertheless, a tendency toward increased prevalence of HBV infection was observed among general population subgroup (adjusted OR, 1.41; 95% CI, 0.98–2.03) and IV drug users (adjusted OR, 1.46; 95% CI, 1.16–1.83).

HIV infection and syphilis

A total of 20 studies that reported HIV serostatus were meta-analyzed (Fig 2C). HIV infection was markedly more prevalent in the tattooed group than in the non-tattooed group (meta-analyzed OR, 3.55; 95% CI, 2.34–5.39). However, only the general population (meta-analyzed OR, 2.73; 95% CI, 1.35–5.54) and the prisoners (meta-analyzed OR, 4.29; 95% CI, 3.32–5.54) showed a statistical significance in the subsequent subgroup analyses (Table 2). For syphilis infection, only 3 studies were identified (Fig 2D). Although syphilis tended to be more prevalent in the tattooed group, it did not reach statistical significance (OR, 1.55; 95% CI, 0.76–3.17). In addition, a subgroup analysis for the study population could not be performed because of the insufficient number of studies.

Discussion

Our systematic review investigated the association between having a tattoo and TTDs. Previous systematic reviews reported a possible positive association between tattooing and each TTD [18]. For HCV infection, two previous studies reported positive associations with having a tattoo, with pooled ORs of 2.74 (95% CI, 2.38–3.15) [19] and 2.79 (95% CI, 2.46–3.18) [17], respectively. In addition, HIV infection has been reported to be more prevalent in tattooed subjects [22]. However, a literature search for syphilis in tattooed subjects is lacking.

In line with previous studies, the results of our study show that the likelihood of having TTDs (HCV, HBV, and HIV infections) among subjects with tattoos is higher than that of the non-tattooed population. This result is consistent with the known knowledge that sharing needles, syringes, or other equipment to inject drugs that may have come in contact with another person’s blood is a high-risk factor for TTDs [2326]. This result was unchanged even after additional adjustment for possible publication bias. Furthermore, we categorized the included studies into TTD subgroups in the general population, hospital patient, blood donor, IV drug user, and prisoner groups to elucidate the specific factors that may have been involved in the spread of TTDs. For HCV infection, all subgroups showed a significant increase in disease transmission rate among the patients with tattoos. However, for HBV infection, only the IV drug user and prisoner groups showed a significant increase in disease incidence rate in the subjects with tattoos after adjusting for publication bias. The prevalence of HIV infection was significantly increased in the general population and prisoner subgroups, although the hospital patients and IV drug users did not show significant differences between the tattooed and non-tattooed groups. This result could be derived from the small number of studies and the included subjects in each subgroup. In the subgroup analyses, the HCV prevalence rate was highest in the hospital subgroup. Although it was statistically not significant, the HIV infection rate was also highest in the hospital subgroup. This may be attributable to the distinguishable characteristic of hospital patients of having awareness of or concern about their illness or symptoms. The IV drug user and prisoner subgroups showed marked increases in the prevalence rates of HCV, HBV, and HIV infections in the tattooed group as compared with the non-tattooed group. Long et al. [27] reported in 2011 that the proportion of prison entrants with tattoos increased with the increasing time spent in the Irish prison over 10 years. They also reported that prisoners who had spent >3 of 10 years were significantly more likely to test positive for HIV antibodies. Adjei et al. [28] also reported that the prevalence rates of HCV, HBV, and HIV infections among prison inmates independently correlated with IV drug use and being incarcerated for >36 months. One study proposed that prisoners tended to be involved in incautious IV drug use because they are exposed to risk behaviors and peer pressures without the concept of sanitation [29]. These results further infer that subjects with tattoos may be associated with increased exposure to unhygienic IV drug use, which leads to the spread of TTDs. Furthermore, a study showed that opioid-substituted treatment in prison led to a reduction in IV injection-associated HIV risk behaviors such as injecting drugs or sharing needles [30]. Overall, although our study did not differentiate prison inmates with tattoos before and after the incarceration, the results imply that prisoners and IV drug users who might have been exposed to an unsafe environment during tattooing could contribute to the increased prevalence of TTDs.

The association of having a tattoo with HBV infection, although some data indicated statistical significance, was not evident compared to the patients with HCV and HIV infections. We assumed that this tendency is attributed to the availability of vaccines for HBV, unlike HCV and HIV, for which vaccines are not yet available. Gahrton et al. [31] reported that the proportion of prisoners in Stockholm who had received HBV vaccination was estimated to be 40.6%. Vaccination prior to the infection may have played a protective role and decreased the overall morbidity of HBV infection. Information on each subject’s vaccination history could be useful for evaluating the independent effect of vaccination in future analysis. Moreover, the included studies were predominantly from countries with low HBV prevalence rates [32]. For instance, the largest number of papers and subjects included for HBV infection analysis were from Iran, where the HBV prevalence was <2% [32]. Moreover, among all the included subjects, 59% were from countries with low HBV prevalence rates (<2%), which might have led to reduced statistical power.

For syphilis infection, the prevalence rate was not significantly higher among subjects with tattoos compared to those without tattoos. Although this might be primarily attributed to the small number of studies for the evaluation, several other elements must be considered. First, all the involved studies used screening tests for the diagnosis of syphilis infection. With these non-treponemal tests with high sensitivity [3335], false-positive cases should be ruled out through confirmatory treponemal tests such as the fluorescent treponemal antibody-absorbed test or Treponema pallidum particle agglutination test [25, 3335]. Second, the characteristic cutaneous manifestations of syphilis may lead to earlier recognition and initiation of interventions that can provide cure and thus cause negative screening test results [33, 34].

Our results raise other possibilities that could lead to an elevated incidence of TTDs in the tattooed population. Drews et al. [36] investigated behavioral differences in tattooed and non-tattooed college students using self-evaluation questionnaires. The tattooed male students’ responses showed increased incidence of participation in risky behaviors, presence of more sexual partners, and higher arrest rates. The responses of tattooed females revealed an increased incidence of drug use and body piercings. These behaviors may also have been associated with the increased prevalence of TTDs.

From the perspective of the intrinsic properties of observational studies, this study has several limitations. First, the heterogeneity of the included meta-analyzed studies was considerably high. Second, we did not evaluate other databases (e.g., language-restricted and gray literature), which could have enabled us to access further epidemiological information. In addition, too few studies regarding syphilis in subjects with and without tattoos were available for the meta-analysis. Moreover, other behavioral factors (e.g., multiple sex partners), which are more common in tattooed subjects, might have been confounding factors and led to an overestimation of the effect of tattooing in TTD prevalence. Establishing a temporal relationship between having a tattoo and the morbidity of TTDs is also essential; however, we could not clarify this relationship owing to the lack of information in the included studies. Nevertheless, our study has strengths in that it presents a comprehensive review of a large number of studies covering various TTDs with a consistent methodology, and comprises and summarizes updated studies on the relationship between having tattoos and TTDs.

In conclusion, this study suggests that TTDs are more prevalent in people with tattoos than in those without tattoos. Apart from the hazardous effects of the tattoo materials themselves, the unhygienic conditions in which the procedures are performed may be associated with the spread of TTDs. Our study results support the idea that having a tattoo could be a risk factor for TTDs.

Supporting information

S1 File. Search strategies for database.

(DOCX)

S1 Table. Characteristics and main findings of the included studies.

(DOCX)

S2 Table. Target diseases and related findings of the included studies.

(DOCX)

S3 Table. Quality assessment of analytical studies that used the adapted Newcastle-Ottawa scale for cross-sectional studies.

(DOCX)

S1 Checklist. PRISMA 2009 checklist.

(DOC)

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

EHC was supported by the Korean Dermatology Research Foundation (2019). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Doss K, Ebesu Hubbard AS. The communicative value of tattoos: The role of public self-consciousness on tattoo visibility. Commun Res Rep. 2009; 26(1):62–74. 10.1080/08824090802637072. [DOI] [Google Scholar]
  • 2.Silver E, VanEseltine M, Silver SJ. Tattoo acquisition: A prospective longitudinal study of adolescents. Deviant Behav. 2009; 30(6):511–38. 10.1080/01639620802467771. [DOI] [Google Scholar]
  • 3.Kluger N, Seite S, Taieb C. The prevalence of tattooing and motivations in five major countries over the world. J Eur Acad Dermatol Venereol. 2019; 33(12):e484–e6. 10.1111/jdv.15808 . [DOI] [PubMed] [Google Scholar]
  • 4.Laumann AE, Derick AJ. Tattoos and body piercings in the United States: a national data set. J Am Acad Dermatol. 2006; 55(3):413–21. 10.1016/j.jaad.2006.03.026 . [DOI] [PubMed] [Google Scholar]
  • 5.Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996; 334(26):1685–90. 10.1056/NEJM199606273342601 . [DOI] [PubMed] [Google Scholar]
  • 6.Schmidt PJ. Syphilis, a disease of direct transfusion. Transfusion. 2001; 41(8):1069–71. 10.1046/j.1537-2995.2001.41081069.x . [DOI] [PubMed] [Google Scholar]
  • 7.Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis–United States, 2016. April 16, 2018. Available: https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm. Accessed July 7 2020.
  • 8.Centers for Disease Control and Prevention. HIV Surveillance Report, 2018 (Updated); vol. 31. May 2020. Available: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed July 7 2020.
  • 9.Alvarado-Esquivel C, Sablon E, Martinez-Garcia S, Estrada-Martinez S. Hepatitis virus and HIV infections in inmates of a state correctional facility in Mexico. Epidemiol Infect. 2005; 133(4):679–85. 10.1017/s0950268805003961 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Coppola RC, Masia G, Pradat P, Trepo C, Carboni G, Argiolas F, et al. Impact of hepatitis C virus infection on healthy subjects on an Italian island. J Viral Hepat. 2000; 7(2):130–7. 10.1046/j.1365-2893.2000.00199.x . [DOI] [PubMed] [Google Scholar]
  • 11.Matos SB, Jesus AL, Pedroza KC, Sodre HR, Ferreira TL, Lima FW. Prevalence of serological markers and risk factors for bloodborne pathogens in Salvador, Bahia state, Brazil. Epidemiol Infect. 2013; 141(1):181–7. 10.1017/S0950268812000386 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Bhate P, Saraf N, Parikh P, Ingle M, Phadke A, Sawant P. Cross sectional study of prevalence and risk factors of hepatitis B and hepatitis C infection in a rural village of India. Arq Gastroenterol. 2015; 52(4):321–4. 10.1590/S0004-28032015000400013 . [DOI] [PubMed] [Google Scholar]
  • 13.de Nishioka SA, Gyorkos TW, Joseph L, Collet JP, MacLean JD. Tattooing and transfusion-transmitted diseases in Brazil: a hospital-based cross-sectional matched study. Eur J Epidemiol. 2003; 18(5):441–9. 10.1023/a:1024277918543 . [DOI] [PubMed] [Google Scholar]
  • 14.Myo K, San San O, Oo KM, Shimono K, Koide N, Okada S. Prevalence and factors associated with hepatitis C virus infection among Myanmar blood donors. Acta Med Okayama. 2010; 64(5):317–21. 10.18926/AMO/40507 . [DOI] [PubMed] [Google Scholar]
  • 15.Shittu AO, Olawumi HO, Issa BA, Nwabuisi C, Durotoye IA, Yussuf AD, et al. Risk factors and sero-prevalence of hepatitis B surface antigen among blood donors in University of Ilorin Teaching Hospital, Ilorin, Nigeria. East Afr Med J. 2014; 91(2):57–61. . [PubMed] [Google Scholar]
  • 16.Mendez-Sanchez N, Motola-Kuba D, Zamora-Valdes D, Sanchez-Lara K, Ponciano-Rodriguez G, Uribe-Ramos MH, et al. Risk factors and prevalence of hepatitis virus B and C serum markers among nurses at a tertiary-care hospital in Mexico City, Mexico: a descriptive study. Ann Hepatol. 2006; 5(4):276–80. . [PubMed] [Google Scholar]
  • 17.Khodadost M, Maajani K, Arabsalmani M, Mahdavi N, Tabrizi R, Alavian SM. Is tattooing a risk factor for hepatitis c transmission?: An updated systematic review and meta-analysis. Hepat Mon. 2017; 17(9):e14308. 10.5812/hepatmon.14308. [DOI] [Google Scholar]
  • 18.Jafari S, Buxton JA, Afshar K, Copes R, Baharlou S. Tattooing and risk of hepatitis B: a systematic review and meta-analysis. Can J Public Health. 2012; 103(3):207–12. 10.1007/bf03403814 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis. 2010; 14(11):e928–40. 10.1016/j.ijid.2010.03.019 . [DOI] [PubMed] [Google Scholar]
  • 20.Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008; 62(4):305–13. 10.1136/jech.2006.051599 . [DOI] [PubMed] [Google Scholar]
  • 21.Ho PJ, Gernaat SAM, Hartman M, Verkooijen HM. Health-related quality of life in Asian patients with breast cancer: a systematic review. BMJ Open. 2018; 8(4):e020512. 10.1136/bmjopen-2017-020512 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Rahimi J, Gholami J, Amin-Esmaeili M, Fotouhi A, Rafiemanesh H, Shadloo B, et al. HIV prevalence among people who inject drugs (PWID) and related factors in Iran: a systematic review, meta-analysis and trend analysis. Addiction. 2020; 115(4):605–22. 10.1111/add.14853 . [DOI] [PubMed] [Google Scholar]
  • 23.Dienstag JL. Acute viral hepatitis. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL et al., editors. Harrison’s Principles of Internal Medicine, 20e. New York, NY: McGraw-Hill Education; 2018. [Google Scholar]
  • 24.Fauci AS, Folkers GK, Lane HC. Human immunodeficiency virus disease: AIDS and related disorders. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL et al., editors. Harrison’s Principles of Internal Medicine, 20e. New York, NY: McGraw-Hill Education; 2018. [Google Scholar]
  • 25.Lukehart SA. Syphilis. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL et al., editors. Harrison’s Principles of Internal Medicine, 20e. New York, NY: McGraw-Hill Education; 2018. [Google Scholar]
  • 26.Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019; 4(6):435–44. 10.1016/S2468-1253(19)30085-8 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Long J, Allwright S, Barry J, Reynolds SR, Thornton L, Bradley F, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey. BMJ. 2001; 323(7323):1209–13. 10.1136/bmj.323.7323.1209 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Adjei AA, Armah HB, Gbagbo F, Ampofo WK, Boamah I, Adu-Gyamfi C, et al. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: A national multicenter study. BMC Infect Dis. 2008; 8(33. 10.1186/1471-2334-8-33 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Calzavara L, Ramuscak N, Burchell AN, Swantee C, Myers T, Ford P, et al. Prevalence of HIV and hepatitis C virus infections among inmates of Ontario remand facilities. CMAJ. 2007; 177(3):257–61. 10.1503/cmaj.060416 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Larney S. Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction. 2010; 105(2):216–23. 10.1111/j.1360-0443.2009.02826.x . [DOI] [PubMed] [Google Scholar]
  • 31.Gahrton C, Westman G, Lindahl K, Ohrn F, Dalgard O, Lidman C, et al. Prevalence of viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm county. BMC Infect Dis. 2019; 19(1):955. 10.1186/s12879-019-4581-3 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.World Health Organization. Global Hepatitis Report 2017. Geneva, Switzerland: World Health Organization; 2017. [Google Scholar]
  • 33.Calonge N, U. S. Preventive Services Task Force. Screening for syphilis infection: recommendation statement. Ann Fam Med. 2004; 2(4):362–5. 10.1370/afm.215 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Golden MR, Marra CM, Holmes KK. Update on syphilis: resurgence of an old problem. JAMA. 2003; 290(11):1510–4. 10.1001/jama.290.11.1510 . [DOI] [PubMed] [Google Scholar]
  • 35.Cantor AG, Pappas M, Daeges M, Nelson HD. Screening for syphilis: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016; 315(21):2328–37. 10.1001/jama.2016.4114 . [DOI] [PubMed] [Google Scholar]
  • 36.Drews DR, Allison CK, Probst JR. Behavioral and self-concept differences in tattooed and nontattooed college students. Psychol Rep. 2000; 86(2):475–81. 10.2466/pr0.2000.86.2.475 . [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Maria R Khan

20 Jul 2021

PONE-D-21-05095

Increased prevalence of transfusion-transmitted diseases among people with tattoos: A systematic review and meta-analysis

PLOS ONE

Dear Dr. Choi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 03 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Maria R. Khan, PhD, MPH

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

3. During our internal review, we noticed you have overlapping text with an abstract of your work published here:

http://www.papersearch.net/thesis/article.asp?key=3845077

PLOS ONE cannot (re)publish material without sufficient permission from the original copyright holder to publish under a CC BY license. Please provide proof that the owner of the content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. You may have the following form completed by the owner as proof: https://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf. Alternatively, you may electronically request permissions electronically from the copyright owner and send us proof of approval, as long as the approval clearly shows that the owner has approved of the CC BY license being applied to their content. Please see https://journals.plos.org/plosone/s/licenses-and-copyright for more information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This article appears to be a rigorously conducted literature review. You accessed observational data comparing tattooed populations to non-tattooed populations to determine prevalence of Hepatitis B, C, HIV and syphilis. However, a few of the statements in your conclusion suggest causation, and you have not been able to determine causation via this literature review, only association. For example, on page 12, lines 202-206, you state that: "the incidence of TTDs in the tattooed population is higher than in the general population BECAUSE having or performing tattoos is a modifiable factor for preventing the spread of such diseases...our study indicates an INCREASE IN THE RISK OF TTDs among subjects with tattoos." Finally, at the end of the Discussion section, page 15, lines 274-275, you state: "tattooing procedures performed under unhygienic conditions SEEM TO BE THE CORE MATTER IN THE SPREAD OF TTDs."

I interpret these statements as indicating that tattooing is responsible for the spread of TTDs, but I don't believe the is what your data show. Instead, they show that the likelihood of having a TTD is higher among those with tattoos, but there is no causal evidence in your review. The authors try to address this by doing analyses with different sub-populations, such as prisoners and IV drug users. However, there is no statement in the article that addresses the possibility that other behaviors that may be more common among people with tattoos could be responsible for the spread of TTDs and there was no discussion of the conditions under which the people in these studies were tattooed (ie, there is a huge difference between getting a tattooed from a licensed artist who has received training on prevention of communicable diseases and an untrained person in a prison who is not using sterilized, single-use equipment). In addition, there is no discussion of the timing of the TTD transmission and the tattoo. For these reasons, that statements mentioned above should be reworded to be clear that there was no proof of causation, but only association. I do not see a limitations section either where you could acknowledge that there could be other behaviors that predisposed these individuals to TTDs.

Additionally, it would be useful if you define the term "community-dweller" as it is not immediately clear to the reader who is being described by this term.

Reviewer #2: The authors have conducted a systematic review and meta-analysis to determine the prevalence of transfusion transmitted diseases among people with tattoos. The study adds evidence to increased risk of TTDs associated with tattoos especially HIV. Thank you for the tremendous work.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Rebecca Giguere

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jan 27;17(1):e0262990. doi: 10.1371/journal.pone.0262990.r002

Author response to Decision Letter 0


2 Aug 2021

Review Comments to the Author

Reviewer #1: This article appears to be a rigorously conducted literature review. You accessed observational data comparing tattooed populations to non-tattooed populations to determine prevalence of Hepatitis B, C, HIV and syphilis.

However, a few of the statements in your conclusion suggest causation, and you have not been able to determine causation via this literature review, only association. For example, on page 12, lines 202-206, you state that: "the incidence of TTDs in the tattooed population is higher than in the general population BECAUSE having or performing tattoos is a modifiable factor for preventing the spread of such diseases...our study indicates an INCREASE IN THE RISK OF TTDs among subjects with tattoos." Finally, at the end of the Discussion section, page 15, lines 274-275, you state: "tattooing procedures performed under unhygienic conditions SEEM TO BE THE CORE MATTER IN THE SPREAD OF TTDs."

I interpret these statements as indicating that tattooing is responsible for the spread of TTDs, but I don't believe the is what your data show. Instead, they show that the likelihood of having a TTD is higher among those with tattoos, but there is no causal evidence in your review. The authors try to address this by doing analyses with different sub-populations, such as prisoners and IV drug users.

However, there is no statement in the article that addresses the possibility that other behaviors that may be more common among people with tattoos could be responsible for the spread of TTDs and there was no discussion of the conditions under which the people in these studies were tattooed (ie, there is a huge difference between getting a tattooed from a licensed artist who has received training on prevention of communicable diseases and an untrained person in a prison who is not using sterilized, single-use equipment). In addition, there is no discussion of the timing of the TTD transmission and the tattoo. For these reasons, that statements mentioned above should be reworded to be clear that there was no proof of causation, but only association. I do not see a limitations section either where you could acknowledge that there could be other behaviors that predisposed these individuals to TTDs.

Additionally, it would be useful if you define the term "community-dweller" as it is not immediately clear to the reader who is being described by this term.

Response:

We greatly appreciate your suggestions regarding our manuscript. We have carefully reviewed and updated the text as suggested.

First, we have revised all the sentences that stated or implied a causal relationship between tattooing and TTD infections. The sentence you first pointed out has been deleted. The expressions on page 12, lines 210-212; page 14, lines 242-245; page 16, lines 290-292, have been revised into objective phrases that interpret the results of the data (highlighted in the revised manuscript).

- Page 12, lines 210-212:

In line with previous studies, the results of our study show that the likelihood of having TTDs (HCV, HBV, and HIV infections) among subjects with tattoos is higher than that of the non-tattooed population.

- Page 14, lines 242-245:

Overall, although our study did not differentiate prison inmates with tattoos before and after the incarceration, the results imply that prisoners and IV drug users who might have been exposed to an unsafe environment during tattooing could contribute to the increased prevalence of TTDs.

- Page 16, lines 290-292:

Apart from the hazardous effects of the tattoo materials themselves, the unhygienic conditions in which the procedures are performed may be associated with the spread of TTDs.

Second, we strongly agree with your opinion that other factors may influence the incidence of TTDs. Thus, we have addressed possible confounding factors in the revised manuscript.

A study has scrutinized tattoo-associated behaviors. Drews et al. [1] investigated behavioral differences in tattooed and non-tattooed college students using self-evaluation questionnaires. The tattooed male students’ responses showed increased incidence of participation in risky behaviors, presence of more sexual partners, and higher arrest rates. The responses of tattooed females revealed an increased incidence of drug use and body piercings. These behaviors may also have been associated with the increased prevalence of TTDs.

In addition, establishing a temporal relationship between having a tattoo and the morbidity of the TTDs is also essential; however, we could not clarify this relationship owing to the lack of information in the included studies.

We have added the underlined explanation in the Discussion section and also stated this point as a limitation in our revised manuscript (highlighted, page 15, lines 268-274 and lines 280-285). The limitation section is within discussion section, page 15, lines 275-285.

Lastly, we defined “community-dwellers” as those who live within certain geographic areas, in accordance with the studies included (page 7, lines 124-128).

1. Drews DR, Allison CK, Probst JR. Behavioral and self-concept differences in tattooed and nontattooed college students. Psychol Rep. 2000; 86(2):475-81. https://doi.org/10.2466/pr0.2000.86.2.475 PMID:10840898.

Attachment

Submitted filename: Response_to_Reviewers.docx

Decision Letter 1

Maria R Khan

27 Sep 2021

PONE-D-21-05095R1Increased prevalence of transfusion-transmitted diseases among people with tattoos: A systematic review and meta-analysisPLOS ONE

Dear Dr. Choi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Specifically please see review and revise use of the term "community dweller," which is vague.

Please submit your revised manuscript within four weeks. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Maria R. Khan, PhD, MPH

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for your revisions. You have addressed my comments sufficiently, except that the term "community dweller" is still unclear to me. I believe perhaps you are referring to people who live in urban areas? In which case, you could put urban dwellers or city dwellers? Otherwise, it remains unclear why someone who lives within a certain geographic area would be at higher risk for TTD's, unless you describe some other particular characteristics of those geographic areas.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Rebecca Giguere

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jan 27;17(1):e0262990. doi: 10.1371/journal.pone.0262990.r004

Author response to Decision Letter 1


17 Oct 2021

Reviewers' comments:

Reviewer #1:

Thank you for your revisions. You have addressed my comments sufficiently, except that the term "community dweller" is still unclear to me. I believe perhaps you are referring to people who live in urban areas? In which case, you could put urban dwellers or city dwellers? Otherwise, it remains unclear why someone who lives within a certain geographic area would be at higher risk for TTD's, unless you describe some other particular characteristics of those geographic areas.

Response:

Thank you for your considerate comment.

The term “community-dwellers” was initially defined as people who live within certain geographic areas (urban as well as rural) according to population-based studies. However, we absolutely agree with your comment that this term is vague.

We believe that this community subgroup referred to in population studies could represent the general population, apart from the specific populations and circumstances to which they belong. Other subgroups defined in our study included hospitalized patients, blood donors, intravenous drug users, and prisoners. Such subgroups are within characteristic environments which favor an increased prevalence of TTDs in the tattooed population. Thus, we thought we could evaluate general prevalence by assessing community-based subgroup. Certainly, the community sample was not evenly recruited from all over the world; however, we thought it is worth estimating the prevalence in a sample which can be approximated to the general population.

To convey the meaning of the term properly, we revised the term “community-dwellers” to “general population”.

We added such descriptions and replaced the original term with “general population” in the revised manuscript (Highlighted, lines 126-130)

Attachment

Submitted filename: Response_to_Reviewers_Final.docx

Decision Letter 2

Maria R Khan

11 Jan 2022

Increased prevalence of transfusion-transmitted diseases among people with tattoos: A systematic review and meta-analysis

PONE-D-21-05095R2

Dear Dr. Choi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Maria R. Khan, PhD, MPH

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Maria R Khan

17 Jan 2022

PONE-D-21-05095R2

Increased prevalence of transfusion-transmitted diseases among people with tattoos: A systematic review and meta-analysis

Dear Dr. Choi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Maria R. Khan

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Search strategies for database.

    (DOCX)

    S1 Table. Characteristics and main findings of the included studies.

    (DOCX)

    S2 Table. Target diseases and related findings of the included studies.

    (DOCX)

    S3 Table. Quality assessment of analytical studies that used the adapted Newcastle-Ottawa scale for cross-sectional studies.

    (DOCX)

    S1 Checklist. PRISMA 2009 checklist.

    (DOC)

    Attachment

    Submitted filename: Response_to_Reviewers.docx

    Attachment

    Submitted filename: Response_to_Reviewers_Final.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.

    The final datasheet for extraction, program code used for the quantitative synthesis, and forest plots for individual analyses can be accessed at our public repository at https://doi.org/10.17632/cgpp4fzxhd.1.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES